Regeneron, Sanofi Drop After-Hours as Covid-19 Vaccine Trial Halted

This post was originally published on this site
https://i-invdn-com.akamaized.net/news/sanofi_M_1440051095.jpg

Investing.com — Shares of Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)fell 2.6% and Sanofi (PA:SASY)fell 1.7% in after-hours trading Thursday after the companies said phase 3 of their Covid-19 vaccine trial did not meet endpoints and they would halt the U.S. trial.

Kevzara (sarilumab) 400 mg did not meet primary and key secondary endpoints compared to a placebo. Minor positive trends were seen but were not statistically significant, and countered by negative trends in a subgroup of critical patients.

A trial of patients who received a dose of 800 mg of Kevzara was also halted.

A separate Sanofi-led trial outside the U.S. in hospitalized patients with severe and critical Covid-19 using a different dosing regimen is ongoing.

Add Comment